NEWS
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
-
Abput EGLA Hogan Lovells Advises Shire in ex-U.S. Closing of its US$2.4 billion oncology business sale to Servier S.A.S
20 Mar 2018New York, 4 September 2018 – Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Copyright © Elite Global Legal Alliance SITE BY:GREATGOAL